Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 1;28(1):37-44.
doi: 10.1097/MCP.0000000000000849.

Robotic bronchoscopy and future directions of interventional pulmonology

Erik Folch  1 , Abhinav Mittal  1 , Catherine Oberg  2
Affiliations
Review

Robotic bronchoscopy and future directions of interventional pulmonology

Erik Folch et al. Curr Opin Pulm Med. .

Abstract

Purpose of review: To describe the emerging field of robotic bronchoscopy within advanced diagnostic bronchoscopy. We review the literature available for these two novel platforms to highlight their differences and discuss the impact on future directions.

Recent findings: There are two distinct technologies both known as robotic bronchoscopy. The Monarch robotic-assisted bronchoscopy is based on electromagnetic guidance whereas the Ion robotic-assisted bronchoscopy is founded on shape sensing technology. Although there is ongoing work to explore the capabilities of these systems, studies have shown that both are safe modalities. Furthermore, both hold promise to improve diagnostic yield and may eventually pave the way for therapeutic bronchoscopic ablation in the future.

Summary: Although both platforms fall under the umbrella term of robotic-assisted bronchoscopy, the Monarch and Ion systems are quite unique in their technology. Thus far, both have demonstrated safety, and early data shows promising results for improved diagnostic yield compared to previously advanced bronchoscopy modalities, especially when combined with advanced confirmatory imaging. Future directions may include bronchoscopic ablation of peripheral lesions given the stability and reach of these platforms.

PubMed Disclaimer

References

    1. U.S. Food and Drug1 Administration. 501(k) Premarket Notification - Monarch Endoscopy Platform (Report K173760). March 2018. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173760 .
    1. U.S. Food and Drug Administration. 510(k) Premarket Notification - ion Endoluminal System. Report K192367). November 2019. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K192367 .
    1. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013; 369:910–919.
    1. Tammemagi M, Ritchie AJ, Atkar-Khattra S, et al. Predicting malignancy risk of screen-detected lung nodules-mean diameter or volume. J Thorac Oncol 2019; 14:203–211.
    1. Choi HK, Ghobrial M, Mazzone PJ. Models to estimate the probability of malignancy in patients with pulmonary nodules. Ann Am Thorac Soc 2018; 15:1117–1126.